Literature DB >> 11696169

HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease.

T Suda1, H Katano, G Delsol, C Kakiuchi, T Nakamura, M Shiota, T Sata, M Higashihara, S Mori.   

Abstract

Multicentric Castleman's disease (MCD) is a clinicopathologically defined entity characterized by systemic lymphadenopathy with unique pathomorphology such as angiosclerosis, blood vessel proliferation in and around follicles, and plasmacytosis. While its pathogenesis has remained unclarified for many years, identification of the human herpesvirus 8 (HHV-8) in at least some MCD cases has opened new perspectives in this field. Because previous reports have described many inconsistencies regarding HHV-8 positivity in MCD, we intended to clarify this issue by the introduction of more convincing methodologies. For this investigation, we introduced two antibodies produced in our laboratories that recognize a latent gene product ORF73 and a lytic gene product ORF59, together with two well-recognized methods, in situ hybridization for the detection of lytic phase transcript T1.1/nut-1, and genomic polymerase chain reaction (PCR). Eighty-two cases of MCD were collected from Japan (n = 75) and France (n = 7). In three cases, the patients were suffering from acquired immunodeficiency syndrome (AIDS). Immunohistochemistry and in situ hybridization showed identical results: only three out of 82 cases were positively stained, and all the positive cases were found to be the patients with AIDS. Genomic PCR was done in 43 cases, and only one case produced positive results: the only AIDS case among the 43 cases studied by genomic PCR. Histopathologically, the HHV-8-positive cases showed the highest intensity of angiosclerosis and germinal center / perifollicular vascular proliferation, while plasmacytosis was not severe in the HHV-8-positive cases. Some of the HHV-8-negative MCD cases displayed similar histopathology, but at a far less intense level, except for the plasmacytosis. These results suggest that: (i) all three of the HHV-8-positive MCD patients in the present group are the patients with AIDS; and (ii) HHV-8-positive MCD patients develop typical but marked angiosclerosis and vascular proliferation that might be differentiated from HHV-8-negative MCD patients, who showed far less intense changes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696169     DOI: 10.1046/j.1440-1827.2001.01266.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  36 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

Review 3.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

Review 4.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

Review 5.  HIV-associated multicentric Castleman disease.

Authors:  Deepa Reddy; Ronald Mitsuyasu
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

Review 6.  TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

Authors:  Gordan Srkalovic; Inga Marijanovic; Maya B Srkalovic; David C Fajgenbaum
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

7.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

8.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

Review 9.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

10.  Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.

Authors:  Bomi Kim; Yoon Kyung Jeon; Chul Woo Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.